NASDAQ
CGTX

Cognition Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Cognition Therapeutics Inc Stock Price

Vitals

Today's Low:
$1.43
Today's High:
$1.4976
Open Price:
$1.43
52W Low:
$1.07
52W High:
$3.83
Prev. Close:
$1.44
Volume:
8798

Company Statistics

Market Cap.:
$86.66 million
Book Value:
1.222
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-51.64%
Return on Equity TTM:
-56.15%

Company Profile

Cognition Therapeutics Inc had its IPO on 2021-10-08 under the ticker symbol CGTX.

The company operates in the Healthcare sector and Biotechnology industry. Cognition Therapeutics Inc has a staff strength of 22 employees.

Stock update

Shares of Cognition Therapeutics Inc opened at $1.43 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.43 - $1.5, and closed at $1.44.

This is a 0% increase from the previous day's closing price.

A total volume of 8,798 shares were traded at the close of the day’s session.

In the last one week, shares of Cognition Therapeutics Inc have slipped by -7.69%.

Cognition Therapeutics Inc's Key Ratios

Cognition Therapeutics Inc has a market cap of $86.66 million, indicating a price to book ratio of 1.9673 and a price to sales ratio of 0.

In the last 12-months Cognition Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-43025000. The EBITDA ratio measures Cognition Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cognition Therapeutics Inc’s operating margin was 0% while its return on assets stood at -51.64% with a return of equity of -56.15%.

In Q1, Cognition Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cognition Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.29 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cognition Therapeutics Inc’s profitability.

Cognition Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.3479. Its price to sales ratio in the trailing 12-months stood at 0.

Cognition Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$45.66 million
Total Liabilities
$7.47 million
Operating Cash Flow
$-41000.00
Capital Expenditure
$41000
Dividend Payout Ratio
0%

Cognition Therapeutics Inc ended 2024 with $45.66 million in total assets and $0 in total liabilities. Its intangible assets were valued at $45.66 million while shareholder equity stood at $35.78 million.

Cognition Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $7.47 million in other current liabilities, 29000.00 in common stock, $-121573000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $38.81 million and cash and short-term investments were $38.81 million. The company’s total short-term debt was $584,000 while long-term debt stood at $0.

Cognition Therapeutics Inc’s total current assets stands at $42.80 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.61 million compared to accounts payable of $3.12 million and inventory worth $0.

In 2024, Cognition Therapeutics Inc's operating cash flow was $-41000.00 while its capital expenditure stood at $41000.

Comparatively, Cognition Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.44
52-Week High
$3.83
52-Week Low
$1.07
Analyst Target Price
$7.75

Cognition Therapeutics Inc stock is currently trading at $1.44 per share. It touched a 52-week high of $3.83 and a 52-week low of $3.83. Analysts tracking the stock have a 12-month average target price of $7.75.

Its 50-day moving average was $1.63 and 200-day moving average was $1.98 The short ratio stood at 2.19 indicating a short percent outstanding of 0%.

Around 779.7% of the company’s stock are held by insiders while 4347.6% are held by institutions.

Frequently Asked Questions About Cognition Therapeutics Inc

The stock symbol (also called stock or share ticker) of Cognition Therapeutics Inc is CGTX

The IPO of Cognition Therapeutics Inc took place on 2021-10-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$73.72
-0.8
-1.07%
$134
-2.45
-1.8%
$6.13
-0.01
-0.16%
$0.2
0
+1.09%
$82.68
-0.61
-0.73%
$66
2.5
+3.94%
$3.44
-0.08
-2.27%
$4322.3
-224.35
-4.93%
ENGINEERS INDIA LTD. (ENGINERSIN)
$147.05
-14.4
-8.92%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer’s disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Address

2500 Westchester Avenue, Purchase, NY, United States, 10577